Paracetamol and its metabolites in children and adults with spinal muscular atrophy – a population pharmacokinetic model
The differences in PK between SMA patients and healthy controls could be explained by body weight and the disease itself. SMA patients should be dosed cautiously, ensuring doses do not exceed the recommended body weight adjusted limit.
Authors
- John Vissing (ORCID: https://orcid.org/0000-0001-6144-8544)
- Qiaolin Zhao (ORCID: https://orcid.org/0009-0008-5800-0966)
- Thomas Krag (ORCID: https://orcid.org/0000-0001-9330-668X)
- Mette Cathrine Ørngreen (ORCID: https://orcid.org/0000-0002-2991-6309)
- Marie Mostue Naume (ORCID: https://orcid.org/0000-0002-2483-4785)
- Tessa Munkeboe Hornsyld
- Per Bo Jensen (ORCID: https://orcid.org/0000-0002-2277-1135)
- Karoline Lolk Revsbech (ORCID: https://orcid.org/0000-0002-7796-0005)
- Sissel Sundell Haslund‐Krog (ORCID: https://orcid.org/0000-0001-9003-7816)
- Brenda C. M. de Winter (ORCID: https://orcid.org/0000-0002-4452-8443)
- Christina Engel Hoei‐Hansen (ORCID: https://orcid.org/0000-0002-6191-694X)
- Morten Dunø (ORCID: https://orcid.org/0000-0002-8436-7744)
- Alfred Peter Born
- Morten Hylander Møller
- Helle Holst
Institutions
- University of Copenhagen (DK)
- Novo Nordisk (Denmark) (DK)
- Bispebjerg Hospital (DK)
- Erasmus MC (NL)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- British Journal of Clinical Pharmacology
- Published
- 2025-03-04
- DOI
- https://doi.org/10.1002/bcp.70028
- Citations
- 3
- Primary Topic
- Neurogenetic and Muscular Disorders Research
- Type
- article
- Field-Weighted Citation Impact
- 4.88
Funders
- Elsass Fonden